Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€24.07
18.10.21
€36.00
18.10.22
31.49%
17.11.21

Revenue growth >5% per year expected
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Risky balance sheet
buy
Bayer AG

Start price
Target price
Perf. (%)
€47.19
26.08.21
-
26.08.22
5.16%
17.11.21

buy
Bayer AG

Start price
Target price
Perf. (%)
€47.19
26.08.21
-
26.08.22
5.16%
17.11.21

buy
Adocia

Start price
Target price
Perf. (%)
€7.54
16.11.20
€10.00
16.11.21
18.04%
17.11.21

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Aptevo Therapeutics Inc.

Start price
Target price
Perf. (%)
€35.20
16.11.20
-
16.11.21
-77.34%
17.11.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Innate Pharma

Start price
Target price
Perf. (%)
€4.10
15.11.20
€5.50
15.11.21
7.86%
16.11.21

Could be worthwhile Investment >10% per year
buy
Novo Nordisk A/S

Start price
Target price
Perf. (%)
€72.75
08.07.21
€105.00
08.07.22
36.34%
15.11.21

buy
Novavax Inc.

Start price
Target price
Perf. (%)
€148.30
04.10.21
-
04.10.22
2.14%
15.11.21

Could be worthwhile Investment >10% per year
Some uniques
buy
Valneva SE

Start price
Target price
Perf. (%)
€19.59
31.10.21
€30.00
31.10.22
8.63%
13.11.21

Fair valuation
Very Future proof/growth oriented business model
Could be very worthwhile Investment >20% year
Higher risks for its business
buy
Roche Holding AG GS

Start price
Target price
Perf. (%)
€246.05
11.11.21
-
11.11.22
-
12.11.21

buy
Roche Holding AG GS

Start price
Target price
Perf. (%)
€246.05
11.11.21
-
11.11.22
-
12.11.21

Novavax Inc.

Start price
Target price
Perf. (%)
€117.42
20.10.21
€105.00
20.10.22
24.32%
11.11.21

Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€29.35
15.03.21
€50.00
15.03.22
43.43%
09.11.21

Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€29.35
15.03.21
€50.00
15.03.22
43.43%
09.11.21

Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
buy
Virbac S.A.

Start price
Target price
Perf. (%)
€395.50
25.10.21
€480.00
25.10.22
1.52%
07.11.21

Could be worthwhile Investment >10% per year
buy
Aptevo Therapeutics Inc.

Start price
Target price
Perf. (%)
€42.00
19.11.20
€50.00
19.11.21
-67.07%
07.11.21

Could be very worthwhile Investment >20% year
Aphria Inc.

Start price
Target price
Perf. (%)
€4.70
05.11.20
-
05.11.21
170.32%
06.11.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Omeros Corp.

Start price
Target price
Perf. (%)
€5.21
19.10.21
-
19.10.22
19.09%
05.11.21

Could be worthwhile Investment >10% per year
buy
Deciphera Pharmaceuticals

Start price
Target price
Perf. (%)
€28.40
29.09.21
€40.00
31.12.24
-67.96%
05.11.21

Could be very worthwhile Investment >20% year
buy
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€2.46
03.11.20
€3.50
04.11.21
-4.88%
05.11.21

Could be worthwhile Investment >10% per year
buy
DBV Technologies S.A.

Start price
Target price
Perf. (%)
€3.53
03.11.20
€10.50
04.11.21
51.47%
05.11.21

Could be worthwhile Investment >10% per year
buy
Sorrento Therapeutics Inc.

Start price
Target price
Perf. (%)
€6.15
02.11.20
€13.00
04.11.21
-4.96%
05.11.21

Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Top 10 in its market
Leading role in innovation
buy
Bayer AG

Start price
Target price
Perf. (%)
€42.35
23.10.20
€54.00
04.11.21
17.72%
05.11.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Bayer AG

Start price
Target price
Perf. (%)
€42.35
23.10.20
€54.00
04.11.21
17.72%
05.11.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€177.98
22.10.20
€170.00
04.11.21
-6.03%
05.11.21

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected